Prospective Analysis of the Use of TEG in Stroke Patients

Completed

Conditions studied: Ischemic Stroke, Brain Hemorrhage

In brief

The overall purpose of this study is to evaluate how effective Thromboelastography (TEG) is on identifying ischemic and hemorrhagic stroke patients at increased risk for bleeding after receiving tissue plasminogen activator (tPA), as well as on differentiating between patients in whom optimal thrombolysis has been achieved, and those whom it has not.

Key facts

Study ID

NCT02494726

Run by

The University of Texas Health Science Center, Houston

People needed

178

Starts

2009-11-01

Expected to finish

2014-12-01

Last updated by the study team

2015-07-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• At least 18 years of age or older.
• Symptoms and signs causing measurable neurologic deficit consistent with an acute stroke.
• CT or MRI consistent with stroke (ischemic or hemorrhagic) or with clinical evidence suggesting a stroke.
• For acute ischemic stroke patients, treatment with tPA and TEG blood draw must be done within 4.5 hours of symptom onset.
• For ICH patients, TEG blood draw must be done within 6 hours of symptom onset.

You may not qualify if…

• Contraindication to CT and MRI (ex. inability to lie flat)
• If ICH patient
• Hemorrhage secondary to trauma, arteriovenous malformation (AVM) or crush injury
• Planned surgical evacuation (hemicraniectomy and ventriculostomy allowed).
• Receipt of hemostatic agents (FFP, Cryo, activated factor seven) prior to TEG blood draw.

Where it is running

• The University of Texas Medical School at Houston — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.